Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.36 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.36 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | SMO | Q99835 | 4/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.35 |
| ▸ | TYK2 | P29597 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
| ▸ | MET | P08581 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31504434 | 1.00 | CTSK (0.40) | CTSKCNR2KMT2AFGFR4BRD4 | |
| SCHEMBL21617253 | 0.81 | CNR1 (0.42) | CNR2HPGD | |
| SCHEMBL31504382 | 0.81 | CNR1 (0.42) | CNR2HPGD | |
| SCHEMBL21617254 | 0.80 | FGFR4 (0.38) | CNR2KMT2AFGFR4BRD4PARP10 | |
| SCHEMBL31504370 | 0.80 | CNR2 (0.42) | CNR2KMT2AFGFR4BRD4HPGD | |
| SCHEMBL21617159 | 0.80 | CNR2 (0.42) | CNR2KMT2AFGFR4BRD4HPGD | |
| SCHEMBL21617236 | 0.79 | KMT2A (0.38) | CNR2KMT2ASMOMAPK14TYK2 | |
| SCHEMBL31504454 | 0.79 | KMT2A (0.38) | CNR2KMT2ASMOMAPK14TYK2 | |
| SCHEMBL23308002 | 0.77 | TYK2 (0.39) | CNR2KMT2AGPR132PARP10SMO | |
| SCHEMBL23308016 | 0.76 | CNR2 (0.42) | CNR2KMT2AGPR132SMOMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3820850-B1 | PHENYL/PYRIDYL-N-PHENYL/PYRIDYL DERIVATIVES FOR TREATING A RNA VIRUS INFECTION | ABIVAX (FR) | 2026-04-01 | — | — | EP | disclosed |
| US-12421206-B2 | Aryl-n-aryl derivatives for treating a RNA virus infection | ABIVAX (FR) | 2025-09-23 | — | — | US | disclosed |
| EP-3820850-A1 | PHENYL/PYRIDYL-N-PHENYL/PYRIDYL DERIVATIVES FOR TREATING A RNA VIRUS INFECTION | ABIVAX (FR) | 2021-05-19 | — | — | EP | disclosed |
| US-20210122732-A1 | ARYL-N-ARYL DERIVATIVES FOR TREATING A RNA VIRUS INFECTION | ABIVAX (FR) | 2021-04-29 | — | — | US | disclosed |
| US-20210122732-A1 | ARYL-N-ARYL DERIVATIVES FOR TREATING A RNA VIRUS INFECTION | ABIVAX (FR) | 2021-04-29 | — | — | US | disclosed |
| WO-2020011816-A1 | PHENYL/PYRIDYL-N-PHENYL/PYRIDYL DERIVATIVES FOR TREATING A RNA VIRUS INFECTION | ABIVAX (FR) | 2020-01-16 | — | — | WO | disclosed |
| WO-2020011816-A1 | PHENYL/PYRIDYL-N-PHENYL/PYRIDYL DERIVATIVES FOR TREATING A RNA VIRUS INFECTION | ABIVAX (FR) | 2020-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12421206-B2 | Aryl-n-aryl derivatives for treating a RNA virus infection | NSUN3, CBR3, C1R | CTSK 4431/4885CNR2 496/4885KMT2A 2374/4885 |
| US-20210122732-A1 | ARYL-N-ARYL DERIVATIVES FOR TREATING A RNA VIRUS INFECTION | NSUN3, CBR3, C1R | CTSK 4431/4885CNR2 496/4885KMT2A 2374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.